Molecular Response of ≤10% BCR::ABL1(IS) is predictive of positive outcomes in treatment-resistant patients with chronic phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 optic trial Meeting Abstract
| Authors: | Apperley, J. F.; Cortes, J. E.; Jabbour, E.; Hochhaus, A.; Hughes, T.; Chuah, C.; de Lavallade, H.; Deininger, M. W.; Lipton, J. H.; Lomaia, E.; Maness, L.; Mauro, M.; McCloskey, J.; Moiraghi, B.; Pavlovsky, C.; Rojas, C.; Rousselot, P.; Sacha, T.; Talpaz, M.; Turkina, A.; Sutton, M. U.; Ren, X.; Vorog, A.; Rosti, G. |
| Abstract Title: | Molecular Response of ≤10% BCR::ABL1(IS) is predictive of positive outcomes in treatment-resistant patients with chronic phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 optic trial |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 6760 |
| End Page: | 6762 |
| Language: | English |
| ACCESSION: | WOS:000893223206345 |
| DOI: | 10.1182/blood-2022-157956 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
